文献速递心力衰竭与心肌病

沙库巴曲/缬沙坦相关低血压在射血分数保留或轻度降低心衰患者中的研究

Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection Fraction.
PubMed 文献 · J Am Coll Cardiol · 2024-03-25

PARAGON-HF试验事后分析纳入4796例慢性心衰(LVEF≥45%)患者,比较沙库巴曲/缬沙坦与缬沙坦。637例(13%)发生低血压,沙库巴曲/缬沙坦组更常见(P<0.001)。低血压后心血管死亡和总心衰住院风险(调整RR 1.63; 95%CI 1.27-2.09; P<0.001)及全因死亡风险(调整HR 1.62; 95%CI 1.28-2.05; P<0.001)升高。LVEF修正沙库巴曲/缬沙坦与低血压风险的关联(P交互=0.019),LVEF≥60%患者治疗相关低血压风险更高。

要点

  • 沙库巴曲/缬沙坦组低血压发生率高于缬沙坦组(13% vs 更低,P<0.001)。
  • 发生低血压后心血管死亡/心衰住院及全因死亡风险显著增加。
  • LVEF≥60%患者使用沙库巴曲/缬沙坦的低血压风险更高且获益可能更小。

核心结论

  • 在PARAGON-HF中,与缬沙坦相比,沙库巴曲/缬沙坦治疗患者LVEF越高,低血压风险越高。
  • LVEF正常或偏高患者从沙库巴曲/缬沙坦获得的临床获益可能较小,获益/风险比支持LVEF低于正常者使用。

研究设计与样本

  • PARAGON-HF试验的事后分析,随机对照试验。
  • 纳入4796例慢性心衰(LVEF≥45%)患者,随机接受沙库巴曲/缬沙坦或缬沙坦。
  • 低血压定义为研究者报告的低血压且收缩压<100 mmHg。

主要发现

  • 637例(13%)发生低血压,沙库巴曲/缬沙坦组更常见(P<0.001)。
  • 低血压后心血管死亡和总心衰住院风险调整RR 1.63(95%CI 1.27-2.09; P<0.001)。
  • 低血压后全因死亡风险调整HR 1.62(95%CI 1.28-2.05; P<0.001)。
  • LVEF修正沙库巴曲/缬沙坦与低血压风险的关联(P交互=0.019),LVEF≥60%患者治疗相关低血压风险显著更高。

关键数值与推荐

  • 低血压定义:研究者报告的低血压且收缩压<100 mmHg。
  • LVEF≥60%患者使用沙库巴曲/缬沙坦的低血压风险显著高于缬沙坦。
  • LVEF低于正常者获益/风险比更优。

临床怎么用

  • 对LVEF≥60%的心衰患者,处方沙库巴曲/缬沙坦需更谨慎评估低血压风险与获益。
  • 用药期间应监测血压,尤其LVEF较高者,及时发现低血压并调整治疗。
  • 发生低血压后需警惕心血管死亡和心衰住院风险增加。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Hypotension is a potential adverse effect of sacubitril/valsartan, but there are limited data regarding the predictors and implications of treatment-related hypotension in heart failure (HF) with mildly reduced and preserved ejection fraction. OBJECTIVES: We investigated predictors of treatment-associated hypotension, clinical outcomes after hypotension, and the relationship between left ventricular ejection fraction (LVEF) and incidence of hypotension in the PARAGON-HF (Prospective Comparison of ARNI with ARB Global Outcomes in HF with Preserved Ejection Fraction) trial. METHODS: PARAGON-HF randomized patients with chronic HF (≥45%) to sacubitril/valsartan or valsartan. Following randomization, hypotension was defined as investigator-reported hypotension with a systolic blood pressure <100 mm Hg. Predictors of hypotension were assessed using multivariable Cox models. Associations between hypotension and clinical outcomes were evaluated in time-updated Cox models. The relationship among treatment, LVEF, and incident rates of hypotension and clinical outcomes was estimated using Poisson regression models. RESULTS: Of 4,796 patients in PARAGON-HF, 637 (13%) experienced hypotension, more frequently in the sacubitril/valsartan arm (P < 0.001). Following documented hypotension, patients had higher risk of cardiovascular death and total HF hospitalizations (adjusted RR: 1.63; 95% CI: 1.27-2.09; P < 0.001) and all-cause death (adjusted HR: 1.62; 95% CI: 1.28-2.05; P < 0.001). LVEF modified the association between sacubitril/valsartan and risk of hypotension (Pinteraction = 0.019) such that patients with LVEF ≥60% experienced substantially higher treatment-related risks of hypotension. CONCLUSIONS: In PARAGON-HF, a higher LVEF was associated with an increased risk of hypotension in patients treated with sacubitril/valsartan compared with valsartan. Because these subjects are also less likely to derive clinical benefit from sacubitril/valsartan, our data reinforce that the benefit/risk ratio favors the use of sacubitril/valsartan in patients with LVEF below normal, but not at higher LVEF. (Efficacy and Safety of LCZ696 Compared to Valsartan, on Morbidity and Mortality in Heart Failure Patients With Preserved Ejection Fraction [PARAGON-HF]; NCT01920711).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Foà, Vaduganathan, Claggett, et al. Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection Fraction. J Am Coll Cardiol. 2024. PMID: 38537919. doi:10.1016/j.jacc.2024.02.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。